← Browse by Condition
Medical Condition

retinitis pigmentosa

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for retinitis pigmentosa sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — retinitis pigmentosa Clinical Trials

How many clinical trials are currently recruiting for retinitis pigmentosa?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for retinitis pigmentosa, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for retinitis pigmentosa?
retinitis pigmentosa research spans Phase 1 (3 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a retinitis pigmentosa clinical trial?
Eligibility criteria for retinitis pigmentosa trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
3
Top Sponsors
The Foundation for Orthopaedics and Regenerative Medicine 1 trial
University of Rochester 1 trial
Sheba Medical Center 1 trial
jCyte, Inc 1 trial
Sumitomo Pharma America, Inc. 1 trial

Recruiting Clinical Trials

NCT05147701 Phase 1
Recruiting
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Enrollment
20 pts
Location
Antigua and Barbuda,...
Sponsor
The Foundation for Orthopaedic...
View Trial →
NCT06319872 Phase 1
Recruiting
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Enrollment
15 pts
Location
United States
Sponsor
University of Rochester
View Trial →
NCT02014389
Recruiting
Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
Enrollment
200 pts
Location
Israel
Sponsor
Sheba Medical Center
View Trial →
NCT06912633 Phase 2
Recruiting
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Enrollment
60 pts
Location
United States
Sponsor
jCyte, Inc
View Trial →
NCT06891885 Phase 1, Phase 2
Recruiting
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Enrollment
12 pts
Location
United States
Sponsor
Sumitomo Pharma America, Inc.
View Trial →
NCT06628947 Phase 2
Recruiting
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Enrollment
36 pts
Location
Australia
Sponsor
Kiora Pharmaceuticals, Inc.
View Trial →
NCT02435940
Recruiting
Inherited Retinal Degenerative Disease Registry
Enrollment
20,000 pts
Location
United States
Sponsor
Foundation Fighting Blindness
View Trial →

Related Conditions

retinal dystrophies (2) stargardt disease (2) eye diseases (1) diabetic retinopathy (1) macular degeneration (1) traumatic optic neuropathy (1) optic atrophy (1) alcohol use disorder (1) age related macular degeneration (1) glaucoma (1) eye diseases hereditary (1) retinal disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology